GSK-partnered Alector hit with third neuro failure as Alzheimer’s asset disappoints
Over the last two years, Alector has suffered three setbacks for its neurodegenerative disease pipeline, often forcing the company to downsize.
GSK-partnered Alector hit with third neuro failure as Alzheimer’s asset disappoints Read More »
